Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

Lancet

Volumn 348, Issue 9037, 1996, Pages 1279-1281

  Basser, Russell L ^c   Rasko, John E J ^d   Clarke, Kerrie ^a   Cebon, Jonathan ^a   Green, Michael D ^d   Hussein, Sonay ^d   Alt, Carole ^d   Menchaca, Dora ^b   Tomita, Dianne ^b   Marty, Jenny ^d   Fox, Richard M ^d   Begley, C Glenn ^d  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b AMGEN INC   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMATOCRIT; HOT FLUSH; HUMAN; LETHARGY; LEUKOCYTE COUNT; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREMOR;

EID: 10344235968     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)04471-6     Document Type: Article

References (23)

1. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 369:1994;565-568.
2. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem (Tokyo). 118:1995;229-236.
3. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryopoiesis and thrombopoiesis by the c-mpl ligand. Nature. 369:1994;533-538.
4. Wendling F, Maraskovsky E, Debill N, et al. c-mpl ligaild is a humoral regulator of megakaryopoiesis. Nature. 369:1994;571-574.
5. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell. 77:1994;1117-1124.
6. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA. 91:1994;11104-11108.
7. Delgado C, Francis GE, Fisher D. The uses and properties of peg-linked proteins. Crit Rev Ther Drug Carrier Syst. 9:1992;249-304.
8. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 86:1995;4486-4492.
9. O'Malley CJ, Rasko JEJ, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor (P. E.G-rHuMGDF to humans produces functional platelets that show no evidence of in vivo activation. Blood 1996; in press.
10. Begley G, Basser R, Clarke K, et al. Randomised, double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer after chemotherapy. Pro Am Soc Clin Oncol 1996; 15: 271 (Abstract).
11. Ulich TR, Del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood. 86:1995;971-976.
12. Choi ES, Hokom M, Bartley T, et al. Recombinant human megakaryocyte growth and development factor (rHuM. G.DF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem Cells Dayt 1095; 13: 317-22.
13. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood. 86:1995;54-59.
14. Vadhan-Raj S, Kudelka AP, Garrison L, et al. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 12:1994;707-714.
15. D'Hondt V, Humblet Y, Guillaume T, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebocontrolled, randomized phase Ib study. Blood. 85:1995;2347-2353.
16. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood. 83:1994;2023-2030.
17. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. i:1988;667-672.
18. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-lα on platelet recovery after high-dose carboplatin. N Engl J Med. 328:1993;756-761.
19. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 87:1996;3615-3624.
20. Nicola NA. Cytokine pleiotropy and redundancy; a view from the receptor. Stem Cells Dayt. 12:(suppl 1):1994;3-14.
21. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 55:1995;3509-3512.
22. Chen JC, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood. 55:1995;4054-4062.
23. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor (MGDF) in nonhuman primates. Blood. 87:1996;1833-1844.